Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients

Table 1 Baseline characteristics of the study patients

Characteristics
Age of recipient, years	Median: 46.5 (range: 20–74)
Gender (male) N (%)	57 (66%)
Type of transplant N (%)
Kidney	82 (95.4%)
Kidney + pancreas	4 (4.6%)
Type of donor N (%)
Living	8 (9.3%)
Deceased	78 (90.7%)
Pretransplant donor (D)/recipient (R) CMV serostatus N (%)
D+/R-	18 (20.9%)
D−/R-	1 (1.1%)
D−/R+	8 (9.4%)
D+/R+	59 (68.6%)
Induction therapy N (%)
Thymoglobulin	7 (8.1%)
Basiliximab	62 (72.1%)
None	17 (19.8%)
Maintenance immunosuppression N (%)
Tacrolimus +mycophenolate mofetil + prednisone	77 (89.5%)
Tacrolimus + mycophenolate sodium + prednisone	7 (8.1%)
Cyclosprine A + mycophenolate mofetil + prednisone	1 (1.2%)
Tacrolimus + everolimus + prednisone	1 (1.2%)
The time of VGCV initiation (days), mean ± SD [range]	9 ± 4.7 [0–25]
The time of VGCV discontinuation (days), mean ± SD [range]	92.4 ± 13.1 [53–122]
Duration of antiviral prophylaxis (days), mean ± SD [range]	83.1 ± 13.4 [40–113]
Tacrolimus concentration (ng/mL), mean ± SD [range]
Day 30	10.4 ± 3.7 [0.3–23]
Day 90	9.5 ± 4.5 [0.3–25.2]
Day 360	7.4 ± 2.8 [3.2–22.4]
Allograft function (eGFR; mL/min/1.73 m2), mean ± SD [range]
Day 30	48.7 ± 21.9 [6.7–103.7]
Day 90	50.4 ± 21.0 [8.5–98.9]
Day 360	51.3 ± 20.4 [10.2–96.7]

ISSN: 1471-2334